The Alzheimer's Drug Discovery Foundation (ADDF) funds international drug discovery and development programs led by scientists in both academia and biotechnology. As a biomedical venture philanthropy, the ADDF seeks to fill the critical translational funding gap that exists between basic research and later-stage drug development by funding high-risk, early-stage drug discovery and development projects. The ADDF supports scientists entering the drug discovery field and helps to create new biotechnology companies to accelerate the commercialization of exciting new therapeutics for Alzheimer's disease, dementia and cognitive aging. We seek a return on investment for all of our grants based on the achievement of scientific and/or business milestones. When these milestones are met, funds are returned to the ADDF to increase our ability to support more research.
The ADDF also brings together physicians, scientists and polymakers with conferences designed to stimulate new ideas and approaches in areas of interest. Our ADDF ACCESS program provides a network of contract research organizations (CROs), academic drug discovery centers, research resources and educational tools for researchers in academia and biotechnology. Additionally, it provides a network of consultants and collaborators for ADDF applicants and funded investigators to provide guidance on design and execution of drug discovery programs and on the process of selecting and managing a CRO contract.